Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Tongue Neoplasms 1Stomatitis 1Somatostatinoma 1Radiation Injuries 1Prostatic Neoplasms 1Paraganglioma 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Mediastinal Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Adenoma, Islet Cell 1

Interventions

fluorodopa F 18 4Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × Salts × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡